Novo Nordisk Stock Crashes 22% After Disappoitning Obesity Drug Data. Eli Lilly Shares Soar.
Novo Nordisk stock fell sharply early Friday after the pharmaceutical giant, known for its blockbuster drugs Ozempic and ...
Novo Nordisk to explore CagriSema weight-loss potential in new trial
Novo Nordisk said on Friday it will begin a new trial of its experimental next-generation CagriSema drug in the first half of ...
Novo Nordisk shares plunge after CagriSema obesity drug trial disappoints
Novo Nordisk on Friday revealed disappointing results in a late-stage trial for its experimental next-generation obesity drug ...
Novo Nordisk A/S - share repurchase programme
On 11 November 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No ...
Novo Nordisk A/S: CagriSema demonstrates superior weight loss in adults with obesity or overweight in the REDEFINE 1 trial
Novo Nordisk today announced headline results from REDEFINE 1, a phase 3 trial in the global REDEFINE programme. REDEFINE 1 ...
Novo Nordisk faces stock market bloodbath after weight-loss drug trial disappoints
Novo Nordisk, Europe’s largest company by market value, faced a stock market bloodbath on Friday after disappointing results ...
Weight-loss drugmaker Novo Nordisk’s shares fall on disappointing study
Shares in Danish pharmaceutical giant Novo Nordisk, maker of diabetes and weight-loss treatments Ozempic and Wegovy, plunged ...
Novo Nordisk shares tumble as weight-loss drug trial data disappoints
Patients receiving Mounjaro, also called Zepbound in the US, lost an average of 22.5 per cent of their weight in phase three ...
Novo Nordisk’s drug stumble leaves it suddenly much slimmer
Denmark’s Novo Nordisk and the US’s Eli Lilly on 32.5 and 57.6 times 2024 earnings respectively — are predicated on the fact that their heft will allow them to keep on top of the competition. Novo ...
The Pharma Letter3h
Novo Nordisk touts CagriSema success, but results miss expectations
Denmark’s Novo Nordisk today announced headline results from REDEFINE 1, a Phase III trial in the global REDEFINE program, ...
Novo Nordisk's next-gen obesity drug CagriSema achieves lower weight loss than expected
Novo's share price fell by 19.5% after the announcement of the results on December 20 to their lowest since August 2023 ...
Novo Nordisk's Hybrid Weight Loss Drug Falls Short On Expectations, Stock Plunges
Novo Nordisk's REDEFINE 1 trial shows CagriSema delivers significant weight loss and a favorable safety profile in obesity ...